September 5, 2025International Journal of Clinical Pharmacology and Therapeutics

Empagliflozin and hydralazine-isosorbide dinitrate combination therapy improves outcomes in black patients with heart failure

View Full Paper

Ask AI

Bookmark

Authors

PBPadmamalini BaskaranHoward University MAMohammed AldhaeefiBrigham and Women's Hospital AAAnise AsaadiShiraz University

Discussion

Member takes

Implication

Retrospective cohort analysis shows that empagliflozin and hydralazine-isosorbide dinitrate reduce BNP in Black patients with HFrEF, highlighting potential therapeutic benefits.

Key Points

The combination therapy improves kidney function and lowers mortality in Black patients with HFrEF, suggesting impactful treatment.
Ex vivo analysis shows that empagliflozin and hydralazine-isosorbide dinitrate combination increases cGMP levels significantly compared to hydralazine-isosorbide dinitrate alone.
This therapy may enhance nitric oxide bioavailability and reduce oxidative stress, contributing to better outcomes in heart failure.
The superior benefits of empagliflozin + H-ISDN were specifically noted in the Black population, emphasizing the need for targeted therapies.

Cite This Study

Baskaran et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477cdb8 https://doi.org/10.5414/cp204854

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort analysis shows that empagliflozin and hydralazine-isosorbide dinitrate reduce BNP in Black patients with HFrEF, highlighting potential therapeutic benefits.

Empagliflozin and hydralazine-isosorbide dinitrate combination therapy improves outcomes in black patients with heart failure

Discussion

Member takes

Implication

Key Points

Cite This Study

Empagliflozin and hydralazine-isosorbide dinitrate combination therapy improves outcomes in black patients with heart failure

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider